BIOMERIEUX (EPA:BIM) | WebDisclosure

Basculer en Français

11065	Companies
242727	Keywords
170969	Articles
130679	Press releases

Home
Companies
BIOMERIEUX

REGULATED PRESS RELEASE

published on 11/06/2024 at 09:54, 1 year 10 months ago

Octobre 2024 - Déclaration sur le nombre d'actions composant le capital social et sur le nombre de droits de vote correspondant
bioMérieux informe sur le nombre total de droits de vote et d'actions au 31/10/2024. Les détails sont conformes à la réglementation financière en vigueur

Droits De Vote BioMérieux Actions Règlement Général Informations Mensuelles
BRIEF

published on 10/30/2024 at 07:06, 1 year 10 months ago

BioMérieux Reports Solid Third-Quarter Performance in 2024

Financial Performance Diagnostic Solutions Sales Growth BioMérieux 2024 GO•28 Strategy
BRIEF

published on 10/30/2024 at 07:06, 1 year 10 months ago

BioMérieux : Croissance organique soutenue au troisième trimestre 2024

BioMérieux Croissance Organique Panels BIOFIRE® SPOTFIRE® GO•28
REGULATED PRESS RELEASE

published on 10/30/2024 at 07:01, 1 year 10 months ago

bioMérieux – Third-Quarter 2024 Business Review
bioMérieux reports strong +10.3% organic sales growth, reaching €2,871m in the first nine months of 2024, driven by growth drivers like GO•28 strategic plan and BIOFIRE® respiratory panels. Q3 2024 shows an +11% organic sales growth with confirmation of 2024 full-year revised guidance. CEO Pierre Boulud expresses confidence in achieving targets

BioMérieux Organic Sales Growth 2024 Guidance GO•28 Strategic Plan BIOFIRE Respiratory Panels
REGULATED PRESS RELEASE

published on 10/30/2024 at 07:01, 1 year 10 months ago

bioMérieux – Information financière du 3ème trimestre 2024
bioMérieux annonce une croissance organique de +10,3% au 3ème trimestre 2024, avec une dynamique forte dans les segments cliniques et industriels, confirmant les objectifs annuels. Le Directeur Général souligne la performance dynamique et l'engagement des collaborateurs

BioMérieux Objectifs Annuels Croissance Organique 3ème Trimestre 2024 Segments Cliniques
BRIEF

published on 10/15/2024 at 07:06, 1 year 11 months ago

BioMérieux Receives CE-Marking for VIDAS® Vitamin B12 Test

BioMérieux Diagnostics Vitamin B12 CE-marking VIDAS®
BRIEF

published on 10/15/2024 at 07:06, 1 year 11 months ago

BioMérieux reçoit le marquage CE pour le test VIDAS® VITAMIN B12 TOTAL

BioMérieux Diagnostic In Vitro Vitamine B12 Test VIDAS® Anémie
REGULATED PRESS RELEASE

published on 10/15/2024 at 07:01, 1 year 11 months ago

bioMérieux receives CE-marking for VIDAS® VITAMIN B12 TOTAL, a blood test to measure total Vitamin B12 concentration
bioMerieux announces CE-marking for VIDAS Vitamin B12 Total, an automated blood test to measure total B12 concentration in serum or plasma, aiding in the assessment of B12 status and optimizing patient care

BioMérieux CE-marking VIDAS Vitamin B12 Total Blood Test
REGULATED PRESS RELEASE

published on 10/15/2024 at 07:01, 1 year 11 months ago

bioMérieux obtient le marquage CE du test sanguin VIDAS® VITAMIN B12 TOTAL mesurant la concentration totale de vitamine B12
bioMérieux obtient le marquage CE pour le test sanguin VIDAS VITAMIN B12 TOTAL mesurant la concentration totale de vitamine B12, renforçant leur gamme d'immunoessais

BioMérieux Marquage CE VIDAS Vitamine B12 Test Sanguin
BRIEF

published on 10/08/2024 at 10:45, 1 year 11 months ago

Actualisation du nombre d'actions et de droits de vote de bioMérieux

Marché Financier Droits De Vote BioMérieux Actions Transparence

Accesswire

Published on 09/23/2026 at 22:00, 9 hours 6 minutes ago

Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 12 hours 41 minutes ago

Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 15 hours 24 minutes ago

Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 16 hours 35 minutes ago

First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 16 hours 36 minutes ago

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

View all ACCESSWIRE

EQS Group

Published on 09/24/2026 at 06:30, 36 minutes ago

Forward-looking succession planning at the helm of V-ZUG
Published on 09/24/2026 at 05:55, 1 hour 11 minutes ago

Donghai, China, Brings Crystal and Handcrafted Press-On Nails to Milan Fashion Week
Published on 09/24/2026 at 05:08, 1 hour 58 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3G and 3H
Published on 09/24/2026 at 03:24, 3 hours 41 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: 2026 Notice of Annual General Meeting
Published on 09/23/2026 at 23:00, 8 hours 6 minutes ago

Correction d’un communiqué du 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNONCE LE SUCCÈS DE SON AUGMENTATION DE CAPITAL AVEC MAINTIEN DU DROIT PREFERENTIEL DE SOUSCRIPTION AINSI QU’UN REMBOURSEMENT PARTIEL D’OBLIGATIONS REMBOURSABLES EN ACTIONS

Les Echos

Published on 09/24/2026 at 07:00, 6 minutes ago

bioMérieux Launches SPINCHIP® hs-cTnl, a Major Innovation for the Measurement of High-Sensitivity Cardiac Troponin I and Faster Management of Cardiac Emergencies
Published on 09/24/2026 at 07:00, 6 minutes ago

bioMérieux lance SPINCHIP® hs-cTnl, une innovation majeure pour le dosage hypersensible de la troponine I cardiaque et l’accélération de la prise en charge des urgences cardiaques
Published on 09/23/2026 at 19:46, 11 hours 19 minutes ago

SFPI GROUP: half year 2026 results
Published on 09/23/2026 at 19:46, 11 hours 19 minutes ago

SFPI GROUP: publication des résultats semestriels 2026
Published on 09/23/2026 at 19:14, 11 hours 52 minutes ago

Robust performance from Investments and continued execution of the strategy

View all LES ECHOS COMFI WIRE